omniture
logo
Search
科济生物医药（上海）有限公司 CARSGEN THERAPEUTICS CO LTD
Media Room

Latest News

rss

CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA

SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-01-10 21:50 2596

CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting

SHANGHAI, Dec. 13, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2021-12-13 20:00 4050

CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041

SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2021-11-22 20:00 2000

CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2021-11-15 22:10 5074
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2...

2021-09-20 08:24 8301
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

CARsgen Therapeutics officially listing on HKEX

HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (the "Company", stoc...

2021-06-19 02:57 9330
CARsgen Therapeutics officially listing on HKEX

CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers

SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage bio...

2021-03-01 19:00 3691

CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

SHANGHAI, Dec. 6, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical com...

2020-12-06 19:00 3702

CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December

SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical co...

2020-11-20 19:00 3443

CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates

SHANGHAI, Nov. 2, 2020 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited ("CARsgen"), a leading...

2020-11-02 19:00 3637

CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers

SHANGHAI, Oct. 5, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmace...

2020-10-05 18:00 5334

CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells

SHANGHAI, Aug. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmac...

2020-08-20 18:32 4420

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion

SHANGHAI, Aug. 17, 2020 /PRNewswire/ -- CARsgen Therapeutics, a leader in developing novel CAR-T ce...

2020-08-17 18:00 4122

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma

SHANGHAI, April 27, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharma...

2020-04-27 18:00 5478

CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs

SHANGHAI, Jan 6, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to d...

2020-01-06 18:00 4025